Blog

Beta-Blockers May Enhance Immunotherapy for Melanoma – Medscape

Beta-Blockers May Enhance Immunotherapy for Melanoma
Medscape
Specifically, among 195 patients with metastatic melanoma who were treated with immunotherapy (interleukin-2, cytotoxic t-lymphocyte associated protein 4, and/or programmed cell death-1 agents) between 2000 and 2015, the 5-year overall survival rate

2018-01-12 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.